Epa liposome, preparation method and application thereof

Abstract

The application discloses an EPA liposome and a preparation method and application thereof, and particularly relates to the technical field of cosmetics. The EPA liposome is prepared through self-assembly of liposomes by using the following raw materials in parts by mass: microalgae oil EPA 1-4 parts, epicatechin-3-gallate 1-2 parts, alpha-tocopherol 0.2-1 part, ginsenoside Rg3 0.02-0.1 part, lipids 2-10 parts, emulsifier 1-10 parts, and water is supplemented to 100 parts. The EPA liposome realizes the stable effect of EPA in a composite system such as a cosmetic skin care product, enhances the in-situ antioxidant and protective functions of EPA and slows down the autoxidation of EPA, improves the bioavailability and enhances the anti-aging effect through the synergy of the contained efficacy substances and the design of the nano-liposome.

Description

Technical Field

[0001] This invention belongs to the field of cosmetic technology, specifically relating to an EPA liposome, its preparation method, and its application. Background Technology

[0002] Algal oil EPA, belonging to the omega-3 unsaturated fatty acid family, can reduce oxidative damage, improve endothelial function, alleviate inflammation, and provide in-situ antioxidant and protective functions by enhancing mitochondrial function and biosynthesis, thus holding promise for use in cosmetics to alleviate skin aging. However, EPA is highly susceptible to light, oxygen, excessive heat, metal elements, and free radicals, leading to physicochemical instability such as oxidation, rancidity, and polymerization, which prevents its direct application in cosmetic and skincare complex systems. Therefore, designing and preparing EPA formulations that can maintain stable efficacy in cosmetic and skincare complex systems has become a hot topic.

[0003] Currently, in order to improve the instability of EPA, related technologies have disclosed technical strategies for encapsulating EPA through encapsulation technology. For example, patent application CN118542456A designed and prepared an emulsion for encapsulating EPA with polysaccharides and citrus fibers as composite wall materials, which enhanced the protection and delivery effect of EPA, extended the shelf life, and improved the physicochemical stability of the EPA encapsulation carrier.

[0004] However, common encapsulation technologies such as those mentioned above still have shortcomings in practical applications. For example, the acidity regulators and antioxidants used are generally limited to improving the stability of the encapsulation wall layer, resulting in poor bioefficacy of the EPA encapsulation carrier and greatly affecting the achievement of EPA's in-situ antioxidant and protective functions. Summary of the Invention

[0005] This invention provides an EPA liposome, its preparation method, and its application, aiming to solve the problem of poor bioefficacy of existing EPA carriers.

[0006] To achieve the above objectives, this application discloses the following technical solution:

[0007] A first aspect of the present invention provides an EPA liposome, which is prepared by self-assembly of liposomes using raw materials comprising the following parts by weight:

[0008] Microalgae oil EPA 1-4 parts, epicatechin-3-gallate 1-2 parts, α-tocopherol 0.2-1 part, ginsenoside Rg3 0.02-0.1 parts, lipids 2-10 parts, emulsifier 1-10 parts, water to make up to 100 parts.

[0009] In a possible implementation, the EPA liposomes are prepared by liposome self-assembly using raw materials comprising the following parts by weight:

[0010] Microalgae oil EPA 1-4 parts, epicatechin-3-gallate 1-2 parts, α-tocopherol 0.5-0.8 parts, ginsenoside Rg3 0.05-0.1 parts, lipids 2-10 parts, emulsifier 1-10 parts, water to make up to 100 parts.

[0011] In a possible implementation, the EPA liposomes are prepared by liposome self-assembly using raw materials comprising the following parts by weight:

[0012] Microalgae oil EPA 4 parts, epicatechin-3-gallate 2 parts, α-tocopherol 0.5 parts, ginsenoside Rg3 0.08 parts, lipids 5 parts, emulsifier 6 parts, water to make up to 100 parts.

[0013] In a possible implementation, the lipid is at least one of butyloctyl salicylate, egg yolk lecithin, cholesterol, phosphatidylcholine, and phosphatidylserine.

[0014] In a possible implementation, the lipid is one of a combination of egg yolk lecithin and cholesterol, or a combination of egg yolk lecithin and phosphatidylcholine.

[0015] In a possible implementation, the emulsifier is at least one selected from PE40 hydrogenated castor oil, cocoyl glucoside, polyglycerol-10 stearate, PEG-8 caprylic / capric glyceride, sucrose stearate, and polysorbate-80.

[0016] In a possible implementation, the emulsifier is a combination of polyglycerol-10 stearate and cocoyl glucoside.

[0017] A second aspect of the present invention also provides a method for preparing the EPA liposomes described above, comprising:

[0018] The lipids were dissolved in ethanol and then evaporated under reduced pressure to form a lipid film.

[0019] Emulsifier, microalgae oil EPA, epicatechin-3-gallate, α-tocopherol and ginsenoside Rg3 are added to water and stirred at 40-60℃ to form an aqueous phase;

[0020] The aqueous phase and lipid film were mixed at 40-60°C and then subjected to high-speed shearing to obtain liposome colostrum.

[0021] The liposome colostrum was subjected to high-pressure homogenization to obtain the EPA liposomes.

[0022] In a possible implementation, the high-pressure homogenization process is carried out at a pressure of 500-1000 bar, a temperature of 40-60°C, and a number of homogenization cycles of 3 to 6.

[0023] In a possible implementation, the shearing rate is 8000-10000 rpm and the time is 1-5 min.

[0024] A third aspect of the invention also provides the use of the EPA liposomes described above in the preparation of cosmetics.

[0025] Compared with the prior art, the beneficial effects of the present invention are:

[0026] The EPA liposomes provided by this invention are prepared into nanoliposomes by combining the active ingredients contained in algal oil EPA, epicatechin-3-gallate, α-tocopherol and ginsenoside Rg3, and supplemented with lipids and emulsifiers. Through the synergistic effect of the contained active ingredients and the encapsulation design of nanoliposomes, the EPA achieves stable efficacy in complex systems such as cosmetics and skin care products, while enhancing the in-situ antioxidant and protective functions of EPA and slowing down the self-oxidation of EPA, thereby improving bioavailability and enhancing the anti-aging effect. Specifically, the main active ingredients are algal oil EPA and epicatechin-3-gallate, supplemented by α-tocopherol and ginsenoside Rg3. On one hand, epicatechin-3-gallate synergistically enhances antioxidant function by scavenging free radicals and inhibiting oxidases, thus reducing EPA's auto-oxidative degradation. On the other hand, α-tocopherol synergistically eliminates skin free radicals caused by ultraviolet light, reducing oxidative damage and providing good photoprotection. It also effectively slows down EPA's oxidative degradation rate and improves its bioavailability by binding to free radicals generated by EPA oxidation. Thirdly, ginsenoside Rg3 synergistically regulates the redox balance in the body, enhances cell self-repair, reduces oxidative stress, and effectively enhances EPA's in-situ antioxidant function, achieving a long-lasting anti-aging effect and further expanding EPA's application prospects in the daily chemical industry. Furthermore, this invention improves the encapsulation rate of active ingredients by rationally controlling preparation parameters, specifically through high-speed shearing for simple encapsulation of active ingredients, which reduces the efficiency of oxidative decomposition of active ingredients before they are homogenized into stable liposomes. By combining high-speed shearing and high-pressure homogenization, the uniformity of liposomes can be effectively guaranteed, and the particle size of liposomes can be controlled. Attached Figure Description

[0027] To more clearly illustrate the technical solutions of the embodiments of this application, the accompanying drawings used in the description of the embodiments will be briefly introduced below. Obviously, the accompanying drawings described below are only some embodiments recorded in this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0028] Figure 1 The graph showing the ABTS free radical scavenging rate provided in this application;

[0029] Figure 2 The transdermal absorption effect diagram provided for this application. Detailed Implementation

[0030] The technical solutions of the embodiments of this application will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some, not all, of the embodiments of this application. All other embodiments obtained by those skilled in the art based on the embodiments described in this application without creative effort are within the scope of protection of this application.

[0031] In the following description of this specification, the term "and / or" is used to describe the relationship between related objects, indicating that three relationships can exist. For example, A and / or B can represent: A existing alone, B existing alone, and both A and B existing simultaneously. A and B can be singular or plural; the symbol " / " means "or".

[0032] In the following description of this specification, the term "at least one" means one or more, and "more than one" means two or more. "At least one of the following" or similar expressions mean any combination of such items, including any combination of single or multiple items. For example, "at least one of A, B or C", or "at least one of A, B and C", can mean any one of A, B, C, or A+B, or A+C, or B+C, or A+B+C, where A, B, and C can be single or multiple.

[0033] In the following description of this specification, the sequence of numbers does not imply the order of execution. Some or all steps may be executed in parallel or sequentially. The execution order of each process should be determined by its function and internal logic, and does not constitute any limitation on the execution process of this embodiment.

[0034] In the following description of this specification, numerical ranges should be understood to also specifically disclose each intermediate value between the upper and lower limits of the range. Any stated value or intermediate value within a stated range, as well as each smaller range between any other stated value or intermediate value within said range, are also included in this embodiment, and the upper and lower limits of the smaller ranges may be independently included or excluded from the range.

[0035] Unless otherwise stated, the technical / scientific terms used in this specification have the meanings commonly understood by one of ordinary skill in the art. While this specification describes only preferred materials and methods, any similar or equivalent methods and materials may be used in specific embodiments or test examples. All references to this specification are incorporated by way of citation to disclose and describe the methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.

[0036] Example 1

[0037] This embodiment provides a method for preparing EPA liposomes, specifically including:

[0038] S1: Add 3 parts by weight of egg yolk lecithin and 2 parts by weight of cholesterol to 10 parts by weight of ethanol solution. After stirring magnetically at 400 rpm and at 50°C to form a homogeneous lipid ethanol solution, evaporate the lipid ethanol solution under reduced pressure to form a lipid film.

[0039] S2: Mix 4 parts by weight of polyglycerol-10 stearate, 2 parts by weight of cocoyl glucoside, 4 parts by weight of microalgae oil EPA, 2 parts by weight of epicatechin-3-gallate, 0.5 parts by weight of α-tocopherol, 0.08 parts by weight of ginsenoside Rg3 and the balance of water, and form a homogeneous solution by magnetic stirring at 300 rpm for 30 min at 40°C.

[0040] S3: Add the solution obtained in S2 to the lipid film obtained in S1, and stir magnetically at 500 rpm for 40 min at 40°C to form a homogeneous mixture.

[0041] S4: Place the mixture obtained in S3 at room temperature and shear it at 9000 rpm for 10 min to obtain the liposome colostrum;

[0042] S5: The liposome colostrum obtained in S4 is homogenized three times in a high-pressure homogenizer at a pressure of 600 bar and a temperature of 45°C, and then cooled to room temperature to obtain EPA liposomes.

[0043] Example 2

[0044] This embodiment provides a method for preparing EPA liposomes, specifically including:

[0045] S1: Add 3 parts by weight of egg yolk lecithin and 2 parts by weight of phosphatidylcholine to 10 parts by weight of ethanol solution. After stirring magnetically at 400 rpm and at 50°C to form a homogeneous lipid ethanol solution, evaporate the lipid ethanol solution under reduced pressure to form a lipid film.

[0046] S2: Mix 4 parts by weight of polyglycerol-10 stearate, 2 parts by weight of cocoyl glucoside, 4 parts by weight of microalgae oil EPA, 2 parts by weight of epicatechin-3-gallate, 0.5 parts by weight of α-tocopherol, 0.08 parts by weight of ginsenoside Rg3 and the balance of water, and form a homogeneous solution by magnetic stirring at 300 rpm for 30 min at 40°C.

[0047] S3: Add the solution obtained in S2 to the lipid film obtained in S1, and stir magnetically at 500 rpm for 40 min at 40°C to form a homogeneous mixture.

[0048] S4: Place the mixture obtained in S3 at room temperature and shear it at 9000 rpm for 10 min to obtain the liposome colostrum;

[0049] S5: The liposome colostrum obtained in S4 is homogenized three times in a high-pressure homogenizer at a pressure of 600 bar and a temperature of 45°C, and then cooled to room temperature to obtain EPA liposomes.

[0050] Example 3

[0051] This embodiment provides a method for preparing EPA liposomes, specifically including:

[0052] S1: Add 5 parts by weight of egg yolk lecithin to 10 parts by weight of ethanol solution, stir magnetically at 400 rpm and at 50°C to form a homogeneous lipid ethanol solution, and then evaporate the lipid ethanol solution under reduced pressure to form a lipid film.

[0053] S2: Mix 4 parts by weight of polyglycerol-10 stearate, 2 parts by weight of cocoyl glucoside, 4 parts by weight of microalgae oil EPA, 2 parts by weight of epicatechin-3-gallate, 0.5 parts by weight of α-tocopherol, 0.08 parts by weight of ginsenoside Rg3 and the balance of water, and form a homogeneous solution by magnetic stirring at 300 rpm for 30 min at 40°C.

[0054] S3: Add the solution obtained in S2 to the lipid film obtained in S1, and stir magnetically at 500 rpm for 40 min at 40°C to form a homogeneous mixture.

[0055] S4: Place the mixture obtained in S3 at room temperature and shear it at 9000 rpm for 10 min to obtain the liposome colostrum;

[0056] S5: The liposome colostrum obtained in S4 is homogenized three times in a high-pressure homogenizer at a pressure of 600 bar and a temperature of 45°C, and then cooled to room temperature to obtain EPA liposomes.

[0057] Example 4

[0058] This embodiment provides a method for preparing EPA liposomes, specifically including:

[0059] S1: Add 3 parts by weight of egg yolk lecithin and 2 parts by weight of cholesterol to 10 parts by weight of ethanol solution. After stirring magnetically at 400 rpm and at 50°C to form a homogeneous lipid ethanol solution, evaporate the lipid ethanol solution under reduced pressure to form a lipid film.

[0060] S2: Mix 4 parts by weight of polyglycerol-10 stearate, 2 parts by weight of cocoyl glucoside, 4 parts by weight of microalgae oil EPA, 2 parts by weight of epicatechin-3-gallate, 0.8 parts by weight of α-tocopherol, 0.1 parts by weight of ginsenoside Rg3 and the balance of water, and form a homogeneous solution by magnetic stirring at 300 rpm for 30 min at 40°C.

[0061] S3: Add the solution obtained in S2 to the lipid film obtained in S1, and stir magnetically at 500 rpm for 40 min at 40°C to form a homogeneous mixture.

[0062] S4: Place the mixture obtained in S3 at room temperature and shear it at 9000 rpm for 10 min to obtain the liposome colostrum;

[0063] S5: The liposome colostrum obtained in S4 is homogenized three times in a high-pressure homogenizer at a pressure of 600 bar and a temperature of 45°C, and then cooled to room temperature to obtain EPA liposomes.

[0064] Example 5

[0065] This embodiment provides a method for preparing EPA liposomes, specifically including:

[0066] S1: Add 3 parts by weight of egg yolk lecithin and 2 parts by weight of cholesterol to 10 parts by weight of ethanol solution. After stirring magnetically at 400 rpm and at 50°C to form a homogeneous lipid ethanol solution, evaporate the lipid ethanol solution under reduced pressure to form a lipid film.

[0067] S2: Mix 4 parts by weight of polyglycerol-10 stearate, 2 parts by weight of cocoyl glucoside, 4 parts by weight of microalgae oil EPA, 2 parts by weight of epicatechin-3-gallate, 0.2 parts by weight of α-tocopherol, 0.02 parts by weight of ginsenoside Rg3 and the balance of water, and stir magnetically at 300 rpm for 30 min at 40°C to form a homogeneous solution.

[0068] S3: Add the solution obtained in S2 to the lipid film obtained in S1, and stir magnetically at 500 rpm for 40 min at 40°C to form a homogeneous mixture.

[0069] S4: Place the mixture obtained in S3 at room temperature and shear it at 9000 rpm for 10 min to obtain the liposome colostrum;

[0070] S5: The liposome colostrum obtained in S4 is homogenized three times in a high-pressure homogenizer at a pressure of 600 bar and a temperature of 45°C, and then cooled to room temperature to obtain EPA liposomes.

[0071] Example 6

[0072] This embodiment provides a method for preparing EPA liposomes, specifically including:

[0073] S1: Add 3 parts by weight of egg yolk lecithin and 2 parts by weight of cholesterol to 10 parts by weight of ethanol solution. After stirring magnetically at 400 rpm and at 50°C to form a homogeneous lipid ethanol solution, evaporate the lipid ethanol solution under reduced pressure to form a lipid film.

[0074] S2: Mix 4 parts by weight of polyglycerol-10 stearate, 2 parts by weight of cocoyl glucoside, 4 parts by weight of microalgae oil EPA, 2 parts by weight of epicatechin-3-gallate, 1 part by weight of α-tocopherol, 0.1 parts by weight of ginsenoside Rg3 and the balance of water, and stir magnetically at 300 rpm for 30 min at 40°C to form a homogeneous solution.

[0075] S3: Add the solution obtained in S2 to the lipid film obtained in S1, and stir magnetically at 500 rpm for 40 min at 40°C to form a homogeneous mixture.

[0076] S4: Place the mixture obtained in S3 at room temperature and shear it at 9000 rpm for 10 min to obtain the liposome colostrum;

[0077] S5: The liposome colostrum obtained in S4 is homogenized three times in a high-pressure homogenizer at a pressure of 600 bar and a temperature of 45°C, and then cooled to room temperature to obtain EPA liposomes.

[0078] Comparative Example 1

[0079] This comparative example provides a method for preparing EPA liposomes, specifically including:

[0080] S1: Add 3 parts by weight of egg yolk lecithin and 2 parts by weight of cholesterol to 10 parts by weight of ethanol solution. After stirring magnetically at 400 rpm and at 50°C to form a homogeneous lipid ethanol solution, evaporate the lipid ethanol solution under reduced pressure to form a lipid film.

[0081] S2: Mix 4 parts by weight of polyglycerol-10 stearate, 2 parts by weight of cocoyl glucoside, 4 parts by weight of microalgae oil EPA and the remainder water, and stir magnetically at 300 rpm for 30 min at 40°C to form a homogeneous solution.

[0082] S3: Add the solution obtained in S2 to the lipid film obtained in S1, and stir magnetically at 500 rpm for 40 min at 40°C to form a homogeneous mixture.

[0083] S4: Place the mixture obtained in S3 at room temperature and shear it at 9000 rpm for 10 min to obtain the liposome colostrum;

[0084] S5: The liposome colostrum obtained in S4 is homogenized three times in a high-pressure homogenizer at a pressure of 600 bar and a temperature of 45°C, and then cooled to room temperature to obtain EPA liposomes.

[0085] Comparative Example 2

[0086] This comparative example provides a method for preparing EPA liposomes, specifically including:

[0087] S1: Add 3 parts by weight of egg yolk lecithin and 2 parts by weight of cholesterol to 10 parts by weight of ethanol solution. After stirring magnetically at 400 rpm and at 50°C to form a homogeneous lipid ethanol solution, evaporate the lipid ethanol solution under reduced pressure to form a lipid film.

[0088] S2: Mix 4 parts by weight of polyglycerol-10 stearate, 2 parts by weight of cocoyl glucoside, 4 parts by weight of microalgae oil EPA, 0.5 parts by weight of α-tocopherol, 0.08 parts by weight of ginsenoside Rg3 and the remainder of water, and stir magnetically at 300 rpm for 30 min at 40°C to form a homogeneous solution.

[0089] S3: Add the solution obtained in S2 to the lipid film obtained in S1, and stir magnetically at 500 rpm for 40 min at 40°C to form a homogeneous mixture.

[0090] S4: Place the mixture obtained in S3 at room temperature and shear it at 9000 rpm for 10 min to obtain the liposome colostrum;

[0091] S5: The liposome colostrum obtained in S4 is homogenized three times in a high-pressure homogenizer at a pressure of 600 bar and a temperature of 45°C, and then cooled to room temperature to obtain EPA liposomes.

[0092] Comparative Example 3

[0093] This comparative example provides a method for preparing EPA liposomes, specifically including:

[0094] S1: Add 3 parts by weight of egg yolk lecithin and 2 parts by weight of cholesterol to 10 parts by weight of ethanol solution. After stirring magnetically at 400 rpm and at 50°C to form a homogeneous lipid ethanol solution, evaporate the lipid ethanol solution under reduced pressure to form a lipid film.

[0095] S2: Mix 4 parts by weight of polyglycerol-10 stearate, 2 parts by weight of cocoyl glucoside, 4 parts by weight of microalgae oil EPA, 2 parts by weight of epicatechin-3-gallate and the remainder water, and stir magnetically at 300 rpm for 30 min at 40°C to form a homogeneous solution.

[0096] S3: Add the solution obtained in S2 to the lipid film obtained in S1, and stir magnetically at 500 rpm for 40 min at 40°C to form a homogeneous mixture.

[0097] S4: Place the mixture obtained in S3 at room temperature and shear it at 9000 rpm for 10 min to obtain the liposome colostrum;

[0098] S5: The liposome colostrum obtained in S4 is homogenized three times in a high-pressure homogenizer at a pressure of 600 bar and a temperature of 45°C, and then cooled to room temperature to obtain EPA liposomes.

[0099] Comparative Example 4

[0100] This comparative example provides a method for preparing EPA liposomes, specifically including:

[0101] S1: Add 3 parts by weight of egg yolk lecithin and 2 parts by weight of cholesterol to 10 parts by weight of ethanol solution. After stirring magnetically at 400 rpm and at 50°C to form a homogeneous lipid ethanol solution, evaporate the lipid ethanol solution under reduced pressure to form a lipid film.

[0102] S2: Mix 4 parts by weight of polyglycerol-10 stearate, 2 parts by weight of cocoyl glucoside, 4 parts by weight of microalgae oil EPA, 2 parts by weight of epicatechin-3-gallate, 0.5 parts by weight of α-tocopherol and the balance of water, and stir magnetically at 300 rpm for 30 min at 40°C to form a homogeneous solution.

[0103] S3: Add the solution obtained in S2 to the lipid film obtained in S1, and stir magnetically at 500 rpm for 40 min at 40°C to form a homogeneous mixture.

[0104] S4: Place the mixture obtained in S3 at room temperature and shear it at 9000 rpm for 10 min to obtain the liposome colostrum;

[0105] S5: The liposome colostrum obtained in S4 is homogenized three times in a high-pressure homogenizer at a pressure of 600 bar and a temperature of 45°C, and then cooled to room temperature to obtain EPA liposomes.

[0106] Comparative Example 5

[0107] This comparative example provides a method for preparing EPA liposomes, specifically including:

[0108] S1: Add 3 parts by weight of egg yolk lecithin and 2 parts by weight of cholesterol to 10 parts by weight of ethanol solution. After stirring magnetically at 400 rpm and at 50°C to form a homogeneous lipid ethanol solution, evaporate the lipid ethanol solution under reduced pressure to form a lipid film.

[0109] S2: Mix 4 parts by weight of polyglycerol-10 stearate, 2 parts by weight of cocoyl glucoside, 4 parts by weight of microalgae oil EPA, 2 parts by weight of epicatechin-3-gallate, 0.08 parts by weight of ginsenoside Rg3 and the remainder of water, and stir magnetically at 300 rpm for 30 min at 40°C to form a homogeneous solution.

[0110] S3: Add the solution obtained in S2 to the lipid film obtained in S1, and stir magnetically at 500 rpm for 40 min at 40°C to form a homogeneous mixture.

[0111] S4: Place the mixture obtained in S3 at room temperature and shear it at 9000 rpm for 10 min to obtain the liposome colostrum;

[0112] S5: The liposome colostrum obtained in S4 is homogenized three times in a high-pressure homogenizer at a pressure of 600 bar and a temperature of 45°C, and then cooled to room temperature to obtain EPA liposomes.

[0113] 1. Particle size stability test

[0114] The particle size stability of the samples prepared in Examples 1-6 and Comparative Examples 1-5 was tested. The samples were placed at -18℃, 4℃, room temperature and 40℃ for 30 days. After being placed at the initial state and at -18℃, 4℃, room temperature and 40℃ for 30 days, the particle size was measured at room temperature using a Zetasizer / Nano-ZS90 Malvern nanopotential particle size analyzer. The results are shown in Table 1.

[0115] Table 1: Results of particle size stability test of EPA liposomes

[0116]

[0117]

[0118] As shown in Table 1, the liposomes prepared in Examples 1-6 and Comparative Examples 1-5 have small particle sizes and do not change much under storage temperature. Among them, the sample in Example 1 has the smallest particle size and the most stable particle size under the four storage temperatures.

[0119] 2. Encapsulation rate test

[0120] The liposome samples prepared in Examples 1, 2, and 3 were processed, and the EPA content was obtained by analysis using a Shimadzu GC-2010Plus gas chromatograph. The encapsulation efficiency of the samples was then calculated.

[0121] Table 2: EPA liposome embedding efficiency results

[0122] Group Encapsulation rate (%) Example 1 99.3 Example 2 97.5 Example 3 92.2

[0123] As shown in Table 2, the emulsification and encapsulation rates of Examples 1-2 are relatively similar and significantly higher than that of Example 3, indicating that combining egg yolk lecithin with cholesterol or phosphatidylcholine can improve the encapsulation rate. Meanwhile, Example 1 exhibits the highest emulsification and encapsulation rate, indicating that the combination of egg yolk lecithin and cholesterol provides the best encapsulation effect. Therefore, this invention preferably uses a combination lipid of egg yolk lecithin with cholesterol or phosphatidylcholine, and more preferably, a combination lipid of egg yolk lecithin with cholesterol.

[0124] 3. Antioxidant Experiment

[0125] 10 μL of the analyte was mixed thoroughly with 190 μL of 0.25 mmol / L ABTS working solution / PBS, and the mixture was shaken well to obtain both the ABTS working solution and the PBS solution of the analyte. The mixture was incubated at room temperature for 6 min, and the absorbance was measured at 405 nm. The results were as follows: Figure 1 As shown in Table 3. The absorbance of the ABTS working solution of the analyte is denoted as A1, the absorbance of the PBS solution of the analyte is denoted as A2, and the absorbance of the blank ABTS working solution and blank PBS is denoted as A3; the analyte is the algal oil EPA liposome prepared in the examples and comparative examples. The formula for calculating the ABTS free radical scavenging rate is as follows:

[0126]

[0127] Table 3: Results of ABTS free radical scavenging rate

[0128]

[0129] according to Figure 1 As shown in Table 3, the liposome emulsion prepared in Example 1 had the highest average ABTS free radical scavenging rate of 94.02%, and the ABTS free radical scavenging rates of the examples were all higher than those of the comparative examples. All examples of this invention can scavenge ABTS free radicals and exhibit antioxidant properties.

[0130] 4. Test the degradation rates of EPA in Examples 1-6 and Comparative Examples 1-5.

[0131] The samples prepared in Examples 1-6 and Comparative Examples 1-5 were placed at room temperature for 30 days. After pretreatment at 0, 7, 14, 21 and 30 days, EPA and its degradation products were separated using a Shimadzu LC-20A liquid chromatograph. Quantitative analysis was performed using a UV detector, and the EPA degradation rate was calculated. The results are shown in Table 4.

[0132] Table 4: Degradation rate of EPA

[0133]

[0134] As shown in Table 4, the EPA degradation rate test data of the samples prepared by Examples 1-6 and Comparative Examples 1-5 show that the EPA degradation rate of the samples prepared by Examples 1-6 is relatively slow, and the EPA degradation rate of the sample prepared by Example 1 is the lowest.

[0135] 5. Transdermal absorption test

[0136] In vitro skin permeation assay: The Franz diffusion cell was placed in a transdermal drug diffusion apparatus, and the conditions were set to a constant temperature circulating water bath at 37℃. Mouse skin was laid flat between the supply and receiving cells and fixed with specific clips, with the stratum corneum facing the supply cell and the subcutaneous tissue facing the receiving cell. The receiving cell was filled with 6 mL of receiving solution (PBS, pH 7.2-7.4), air bubbles were removed, and equilibration was carried out at 37℃ and 300 rpm for 1 h. 1 mL of the test sample was added to the supply cell, ensuring that the intact components of the stratum corneum were in contact with the formulation. The supply cell was sealed with a sealing film to prevent formulation evaporation, and the receiving solution was continuously stirred to ensure uniform dispersion of the formulation. 1 mL of the receiving solution was collected at 0, 2, 4, 8, and 24 h, and an equal volume of fresh receiving solution (PBS) was added immediately after each sampling. The collected samples were analyzed by HPLC, and the cumulative permeability per unit skin area was calculated. The specific test results are as follows:

[0137] Cumulative permeation (Q) = (A × V) / A; V is the volume of the receiving chamber (ml); A is the exposed area of ​​the skin sample (cm²).

[0138] Cumulative penetration rate (J): J = Q / (A×t), where Q is the amount of drug that penetrates the skin within time t; A is the exposed area of ​​the skin sample (square centimeters); and t is the experimental time (hours).

[0139] according to Figure 2 It can be seen that after 24 hours of penetration experiment, the cumulative permeation amount and permeability of all samples through mouse skin increased with time. After 24 hours, the cumulative transdermal permeability of Example 1 reached 5.51%, showing the best skin penetration effect.

[0140] The various embodiments in this specification are described in a progressive manner. The same or similar parts between the various embodiments can be referred to each other. Each embodiment focuses on describing the differences from other embodiments.

[0141] The above embodiments are only used to illustrate the technical solutions of this application, and are not intended to limit this application. Although this application has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features therein. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of this application.

Claims

1. An EPA liposome, characterized by, The liposome self-assembly is prepared by molding with raw materials comprising the following parts by mass: Microalgae oil EPA 4 parts, epicatechin-3-gallate 2 parts, alpha-tocopherol 0.5 parts, ginsenoside Rg3 0.08 parts, lipids 5 parts, emulsifiers 6 parts, and water to make up to 100 parts; The lipids are one of a combination of egg yolk lecithin and cholesterol, and a combination of egg yolk lecithin and phosphatidylcholine; The emulsifier is a combination of polyglyceryl-10 stearate and cocoglycoside.

2. A method of preparing the EPA liposome according to claim 1, characterized by, Comprising: The lipids are dissolved in ethanol, and then evaporated under reduced pressure to form a lipid film; The emulsifier, microalgae oil EPA, epicatechin-3-gallate, alpha-tocopherol, and ginsenoside Rg3 are added to water, and stirred at 40-60°C to form an aqueous phase; The aqueous phase and the lipid film are mixed at 40-60°C, and then sheared at high speed to obtain a liposome initial milk; The liposome initial milk is subjected to high-pressure homogenization to obtain the EPA liposome.

3. The production method according to claim 2, characterized by, The high-pressure homogenization is performed at a pressure of 500-1000 bar and a temperature of 40-60°C, and the homogenization is performed 3-6 times. And / or, the shearing is performed at a rate of 8000-10000 rpm for 1-5 min.

4. Use of the EPA liposome of claim 1 in the preparation of a cosmetic product.

Images